Medtronic’s Drug-Eluting Stent CE Marked for One-Month Therapy

Medtronic’s Resolute Onyx drug-eluting stent has earned the CE mark in Europe for a one-month dual-antiplatelet therapy (DAPT) for high bleeding-risk patients following coronary angioplasty.

High bleeding-risk patients on longer DAPT regimens are three times more likely to have bleeding events, the company said.

Medtronic is currently seeking CE mark clearance from the FDA for the one-month therapy.